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Introduction
Docetaxel is an antineoplastic agent that disrupts the microtubular network needed for the normal progression of mitosis.
It binds to free tubulin and promotes formation of the microtubule structure (1) . In this way, the microtubule bundles become stable and their disassembly is interrupted in the normal phase of the cell cycle. This prevents the completion of mitosis, so that docetaxel acts as an antineoplastic agent. Docetaxel is therefore widely used as an antimicrotubule agent to treat solid tumors, especially breast, gastric, and other cancers.
The major dose-related toxicities reported for docetaxel are neutropenia and mucositis (1) . Other reported toxicities include neuropathies, fluid retention, and acute cutaneous reactions. The cutaneous reactions are usually asymptomatic or, in rare cases, mildly symptomatic of impaired function and can include urticaria, pruritis, flushing, hypersensitivity, injection site reaction, acral erythema, and erythrodysesthesia.
Toxicity in the form of skin thickening of the extremities is seldom encountered after docetaxel treatment. We report a case of a rapidly progressing scleroderma-like cutaneous change that occurred in both the upper and lower extremities after docetaxel treatment for breast cancer.
Case Report
A 57-year-old Korean woman was diagnosed with breast cancer (infiltrating ductal carcinoma, grade 2) in a hospital. 
Discussion
We report a case of a Korean female with progressive scleroderma-like cutaneous lesions on the upper and lower extremities after docetaxel chemotherapy for breast cancer. This further suggests a low likelihood that this drug is associated scleroderma-like cutaneous changes. In Koreans, some reports have shown an association between docetaxel and scleroderma-like cutaneous lesions in gastric and ovarian cancer patients (7, 8) . However, no case study has yet reported scleroderma-like cutaneous lesions after docetaxel treatment for breast cancer.
Several studies have suggested that drug-induced scle-roderma could be associated with specific mechanisms. For example, transforming growth factor-beta (TGF-beta) expression and fibroblast activation could be important in scleroderma (9) and could be associated with the progressive fibrosis associated with it. Injury to the vascular endothelium and defective apoptosis of fibroblasts in the skin could also be responsible for scleroderma (10) . Smad proteins are intracellular signaling effectors of the TGF-beta superfamily. Endogenous Smad-2, 3, and 4 molecules bind to microtubules (MTs), and this binding serves as a negative regulatory mechanism to control TGF-beta activity (11) . Disruption of the MT network by chemical agents such as paclitaxel increases TGF-beta-induced Smad activity. Smad3 expression is increased in scleroderma fibroblasts, whereas inhibitory Smad7 is selectively decreased in these fibroblasts (12) .
Our patient had undergone previous treatment when her breast cancer was diagnosed, so some possibility exists that the cutaneous lesion could be associated with malignancy. A strong association has been demonstrated between scleroderma and certain cancers, especially lung cancer and breast cancer (1) . A relationship between paraneoplastic scleroderma and malignancy of the breast, ovary, uterus, and prostate has been reported in small numbers of patients. However, paraneoplastic scleroderma shows a much more rapid and severe progression than do other forms of scleroderma and is associated with a close temporal relationship between the development of scleroderma and malignancy (13) . We cannot find any criteria that would exclude paraneoplastic scleroderma. The skin lesions took over a year to present following the discovery of the patient's malignancy. The edema, the hardening and thickening of the skin on both upper and lower extremities, and the weight gain were almost resolved after the discontinuation of docetaxel. In addition, the cancer was stable at the time of scleroderma diagnosis and the levels of the tumor marker CA 15-3 were normal. A paraneoplastic scleroderma was therefore considered less likely in this case. However, the interpretation of the association between scleroderma and cancer is complicated because some epidemiologic studies have suggested that patients with scleroderma have an increased risk of malignancy (14) .
The scleroderma-like skin lesion observed in this patient was similar to myxedema and scleromyxedema. These are softer, more edematous skin changes and show deposits of mucin within the superficial dermis (15) . The examination of the thickening and hardening of the skin by a physician and the biopsy result showed no evidence of these diseases in this case.
In conclusion, we describe here the first Korean female case of a scleroderma-like cutaneous lesion after docetaxel chemotherapy for breast cancer. Docetaxel is widely used and has been found to have a survival benefit in patients with breast and gastric cancer. The incidence of breast cancer is increasing and the use of docetaxel is expected to increase as well.
In cases of edema and skin thickening of upper and lower extremities after docetaxel chemotherapy for breast cancer, a scleroderma-like cutaneous lesion should be considered as a differential diagnosis. Further study will be needed to determine the details regarding the association between docetaxel and scleroderma-like changes.
Summary
We describe here the first Korean female case of a scleroderma-like cutaneous lesion after docetaxel chemotherapy for breast cancer.
